An interventional study of Teduglutide (ALX-0600) and No Treatment Added in Short Bowel Syndrome (SBS), sponsored by Meyer Children's Hospital IRCCS. Recruiting at 1 site in Italy. Open to participants aged 4 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Meyer Children's Hospital IRCCS · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is the only one with no phase, and was the 20th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country.
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 4 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 50 is above the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
Meyer Children's Hospital IRCCS is the lead sponsor of 79 studies on the registry; 56 are open to participants now.
Meyer Children's Hospital IRCCS has 1 study filed under Short Bowel Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
| NCT07400783Meyer Children's Hospital IRCCSTED_ORG: Study on Short Bowel Syndrome | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to understand why pediatric patients with short bowel syndrome respond differently to treatment with the glucagon-like peptide-2 (GLP-2) analogue teduglutide. Short bowel syndrome is a rare and severe condition in children that results from extensive intestinal resection and leads to impaired nutrient absorption, chronic diarrhea, and dependence on parenteral nutrition. Although teduglutide is known to promote intestinal adaptation and improve absorption, the clinical response varies widely among patients, and the biological mechanisms underlying this variability are not fully understood.
This study aims to investigate the effects of teduglutide using human intestinal organoids derived from intestinal tissue samples of pediatric patients with short bowel syndrome. Intestinal organoids are three-dimensional structures grown from patient-derived stem cells that reproduce key structural and functional characteristics of the human intestine. These organoids provide a human-based experimental model that allows the study of intestinal morphology, cellular behavior, and nutrient absorption in a controlled in vitro environment.
The main questions this study aims to answer are:
Does treatment with teduglutide improve the absorptive capacity of human intestinal organoids derived from pediatric patients with short bowel syndrome?
Are there differences in intestinal structure, cellular proliferation, and gene expression between teduglutide-treated organoids and untreated organoids?
Are specific molecular or cellular features associated with different responses to teduglutide?
Researchers will compare intestinal organoids treated with teduglutide to untreated organoids obtained from the same patients. This comparison will be used to evaluate changes in organoid morphology, expression of receptors involved in intestinal growth and absorption, activity of nutrient transporters, and overall absorptive function. The study will also explore differences between organoids derived from patients who show different clinical responses to teduglutide.
Participants in this study are pediatric patients with short bowel syndrome or patients undergoing intestinal resection surgery as part of their standard clinical care. No experimental treatment is administered directly to participants as part of this study. Intestinal tissue samples are collected only during clinically indicated surgical procedures and are not obtained specifically for research purposes.
Participants will:
Provide intestinal tissue samples collected during routine or clinically indicated intestinal surgery
Have intestinal organoids generated from their tissue samples using established laboratory techniques
Have their organoids studied in vitro with and without exposure to teduglutide to evaluate intestinal structure, gene and protein expression, and nutrient absorption mechanisms
The results of this study are expected to improve understanding of the biological mechanisms underlying variable responses to teduglutide and may contribute to the development of more personalized treatment strategies for pediatric patients with short bowel syndrome in the future.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Human intestinal organoids derived from pediatric patients with short bowel syndrome are treated in vitro with teduglutide to assess its effects on intestinal morphology, gene and protein expression, and nutrient absorption.
Drug: Teduglutide (ALX-0600)
Human intestinal organoids derived from pediatric patients with short bowel syndrome are maintained in vitro without exposure to teduglutide and serve as a control group for comparison.
Other: No Treatment Added
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. In this study, teduglutide is used in vitro on human intestinal organoids derived from pediatric patients with short bowel syndrome. The intervention is applied only to organoid cultures and is not administered directly to study participants. Teduglutide-treated organoids are compared with untreated control organoids to evaluate differences in intestinal structure, gene and protein expression, and nutrient absorption.
No Treatment Added
Intestinal organoid diameter after in vitro exposure to teduglutide
Quantitative measurement of intestinal organoid diameter assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.
Time frame: During in vitro treatment period (up to 7 days)
Crypt-villus-like architecture in intestinal organoids
Quantitative assessment of crypt-villus-like architectural features in patient-derived human intestinal organoids following in vitro exposure to teduglutide, evaluated by image-based morphological analysis and compared with untreated organoids from the same participant.
Time frame: During in vitro treatment period (up to 7 days)
Organoid shape (sphericity) after in vitro teduglutide treatment
Quantitative measurement of organoid shape, expressed as sphericity index, in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.
Time frame: During in vitro treatment period (up to 7 days)
Lumen size in intestinal organoids after in vitro exposure to teduglutide
Quantitative measurement of lumen size assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.
Time frame: During in vitro treatment period (up to 7 days)
Intestinal organoid volume after in vitro exposure to teduglutide
Quantitative measurement of intestinal organoid volume assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.
Time frame: During in vitro treatment period (up to 7 days)
Lumen integrity in intestinal organoids after in vitro exposure to teduglutide
Quantitative assessment of lumen integrity assessed by image-based analysis in patient-derived human intestinal organoids treated in vitro with teduglutide and compared with untreated organoids from the same participant.
Time frame: During in vitro treatment period (up to 7 days)
Started Oct 2024 (actual). Primary completion is estimated for Jan 2027, 27 months after the start.
Of 24 interventional studies with no phase under Short Bowel Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 59. This study's planned 27 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Mar 2026 → Jan 2027 and completion Oct 2026 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide
Meyer Children's Hospital IRCCS